Reports Q2 revenue $589.8M, consensus $569.4M. The company states: "The Company is deploying its first electric fleet during the third quarter and expects to average approximately 31 active fleets for the full quarter. We expect to deploy two more electric fleets in the fourth quarter. There are no current plans to reactivate any conventional or dual fuel fleets for the remainder of 2022. The Company also expects incremental improvement in third quarter results, as compared to the second quarter attributable to further bundling of materials with our pressure pumping services, continued pricing improvements, and the anticipated deployment of our first electric fleet."

"Maintaining our momentum from the first quarter, we continued to execute towards our clinical and corporate milestones, including progress across all of our five clinical-stage product candidates," said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. "In addition, the protocol amendment for the 4D-310 Phase 1/2 clinical trial in Fabry disease will expand access to include female patients, a large and significantly affected patient population with Fabry disease. We have maintained our focus on efficient cash utilization, with current cash available to support our operations into the first half of 2025. Our team is committed to relentless execution as we make progress toward key clinical data readouts in the first half of 2023 and beyond."

The company states: "To date, we have not generated any operating revenue. We expect to begin to generate revenue in 2023 from our commercial plant and PreP facilities."

"Kinnate is making meaningful progress with its proprietary clinical and preclinical precision oncology programs," said Nima Farzan, chief executive officer, Kinnate Biopharma Inc. "We continue to expand the global footprint of clinical trial sites for our pan-RAF inhibitor, KIN-2787, for which we expect to share initial clinical data later this year. The Kinnate Discovery Engine is actively generating new research leads, and with our financial strength, we're well positioned to invest in breakthrough science and long-term growth of the company."